KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查

Updating the MASH pharmacotherapy landscape: a network meta-analysis incorporating SGLT2 inhibitors and emerging combination therapies.

Mengshi Tang, Yingxu Ma, Yating Wang

Front Endocrinol (Lausanne) 17 1829315

PMID42325618
PMCIDPMC13275242
DOI10.3389/fendo.2026.1829315
发表日期2026-06-22
AI 判定该论文不进入自动 KM 提取:This is a network meta-analysis and systematic review, not a report of a single human Phase III randomized controlled clinical trial. The inclusion criteria mention Phase II/III RCTs, but the publication itself is a meta-analysis synthesizing results from multiple studies.
摘要

摘要

BACKGROUND: Multiple pharmacological agents targeting distinct pathways (e.g., GLP-1, FGF21, THR-β) show promise for metabolic dysfunction-associated steatohepatitis (MASH). However, while recent meta-analyses have established the efficacy of GLP-1 RAs and FGF21 analogs, they largely predate critical histological trials on SGLT2 inhibitors, leaving the comparative position of this highly accessible oral therapy undefined. We aimed to systematically rank the efficacy and tolerability of distinct pharmacological mechanisms for MASH and characterize their benefit-risk profiles through cluster analysis. METHODS: We searched PubMed, Embase, Web of Science, Scopus, and Cochrane Library for Phase II/III randomized controlled trials (RCTs) involving adults with biopsy-proven MASH. The primary outcome was fibrosis improvement (≥1 stage reduction without MASH worsening). Secondary outcomes included MASH resolution and safety (discontinuation due to adverse events). A frequentist network meta-analysis (NMA) was performed. RESULTS: We included 34 studies from 33 unique publications. For fibrosis improvement, FGF21 analogs (RR 2.22, 95% CI 1.40-3.54) and SGLT2 inhibitors (RR 2.27, 95% CI 1.22-4.17) ranked highest. Notably, SGLT2 inhibitors numerically outperformed the FDA-approved THR-β agonist (RR 1.61) and GLP-1 RAs (RR 1.51, 95% CI 1.09-2.10). For MASH resolution, GLP-1/GIP dual agonists (RR 5.21) and FGF21 analogs (RR 3.52) showed the highest efficacy, while SGLT2 inhibitors also yielded significant benefits (RR 2.92, 95% CI 1.18-7.26). In the two-dimensional cluster analysis evaluating the balance between fibrosis efficacy and tolerability, SGLT2 inhibitors numerically occupied the "Optimal Zone," though this finding is based on limited histological data. Sensitivity analyses excluding small-scale studies confirmed the robustness of these rankings. CONCLUSION: FGF21 analogs (RR 2.22, 95% CI 1.40-3.54) demonstrated the most robust evidence for fibrosis improvement. Preliminary evidence from a single pivotal trial suggests SGLT2 inhibitors (RR 2.27, 95% CI 1.22-4.17) may represent a promising oral option, though this requires confirmation in adequately powered Phase 3 trials. Further adequately powered Phase 3 trials are warranted to validate the magnitude of these histological benefits. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD420261292638.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。